ライフサイエンスコーパス: serum glucose

1 ression of gluconeogenic genes and decreased serum glucose.

2 after adjustment for diabetes treatment and serum glucose.

3 nsgene reverses the effect of CC ablation on serum glucose.

4 glucose infusion rates to maintain a similar serum glucose.

5 n approach used here in the determination of serum glucose.

6 nderwent hyperinsulinemic clamp to normalize serum glucose.

7 , cataract) and had baseline measurements of serum glucose.

8 cholesterols, triglycerides and decrease the serum glucose.

9 liver masses, hepatic fat accumulation, and serum glucose.

10 using information on hypoglycemic agents and serum glucose.

11 levels, and lowers hepatic triglycerides and serum glucose.

12 ormed to estimate the association of NLR and serum glucose.

13 also significantly related to higher fasting serum glucose.

14 tively randomized to tight glycemic control (serum glucose, 125 to 200 mg/dL) with GIK or standard th

15 , with reduced leptin (20-fold) and elevated serum glucose (3-fold), insulin (50- to 400-fold), free

16 compared with control mice had lower fasting serum glucose (4.8 +/- 0.5 mmol/l in transgenic mice vs.

17 stration to ob/ob mice also markedly reduced serum glucose (8.3 +/- 1.2 vs. 24.5 +/- 3.8 mmol/l; P <

18 Average daily serum glucose, admission serum albumin, time to initiati

19 Serum glucose, ADP fibrinogen, and mannose were among th

20 ine ingestion results in a small decrease in serum glucose and an increase in glucagon and insulin co

21 DL-cholesterols, triglycerides and increased serum glucose and body weight of the animals.

22 ) mice, associated with similar increases in serum glucose and cholesterol.

23 Serum glucose and cholesterol/triglycerides in the liver

24 At 1 year after transplant, the mean serum glucose and creatinine levels were not different b

25 Core temperature, hemodynamics, serum glucose and electrolytes, and P/F were sequentiall

26 to the action of insulin and in normalizing serum glucose and free fatty acids in type 2 diabetic pa

27 s in subgingival plaque and determination of serum glucose and glycated hemoglobin (HbA1c).

28 s classified based on self-report or fasting serum glucose and glycated hemoglobin levels.

29 ocin-treated mice showed increased levels of serum glucose and growth retardation consistent with a s

30 Serum glucose and hepatic steatosis was significantly re

31 Ozone-exposed dams also had lower serum glucose and higher free fatty acid concentrations

32 ing FFAs, which was associated with elevated serum glucose and impaired glucose and insulin tolerance

33 a in Acox1-deficient ob/ob mice also reduces serum glucose and insulin (P<0.05) and improves glucose

34 s of the WHI low-fat dietary intervention on serum glucose and insulin and insulin resistance up to 6

35 iabetes and higher concentrations of fasting serum glucose and insulin are associated with increased

36 The pinitol-enriched beverage reduced serum glucose and insulin at 45 and 60min, but only at a

37 nthropometric measures, dietary assessments, serum glucose and insulin concentrations, homeostasis mo

38 ose of caloric restriction including reduced serum glucose and insulin levels and increased resistanc

39 Fasting serum glucose and insulin levels were measured at 7-day

40 ght gain, with normal maintenance of fasting serum glucose and insulin levels.

41 Serum glucose and insulin samples were measured at basel

42 Serum glucose and insulin were monitored for 5 h posting

43 Levels of serum glucose and insulin were significantly decreased i

44 e physiological impact of different foods on serum glucose and insulin, and such information should r

45 d not result in obesity but led to increased serum glucose and insulin, reduced muscle glucose uptake

46 pregnancy reduced body weight gain, lowered serum glucose and lipid concentration, and improved insu

47 thermogenesis, weight loss and reduction in serum glucose and lipid levels.

48 ared with 33 and 71% who had measurements of serum glucose and lipids, respectively.

49 the partial protection against the elevated serum glucose and obesity seen in type 2 diabetes-like m

50 The association between serum glucose and odds of TOF indicates the need for add

51 in mice, which is associated with decreased serum glucose and triacylglycerol levels.

52 cy, fetal growth restriction, elevated fetal serum glucose and triglyceride levels.

53 lture under stress conditions (withdrawal of serum/glucose and/or antioxidants), OPCs showed increase

54 icant adverse effect on serum lipid, fasting serum glucose, and fasting serum insulin levels, or bloo

55 luded height, weight, blood pressure, random serum glucose, and glycosylated hemoglobin measurements.

56 ange in weight, waist circumference, lipids, serum glucose, and hemoglobin A1c (HbA1c).

57 d profile, cotinine-assessed smoke exposure, serum glucose, and questionnaire data on socioeconomic a

58 ions, and atrial fibrillation), the level of serum glucose, and the incidence of hypoglycemic events.

59 ical records, or baseline HbA(1c) or fasting serum glucose-and risk of new-onset diabetes among those

60 The mean 24-h integrated serum glucose at the end of the control and LoBAG diets

61 titutes of Health Stroke Scale score, higher serum glucose, atrial fibrillation, and any impairment i

62 Serum glucose (average value and maximum value each day)

63 ing for donor age, body mass index, baseline serum glucose, baseline serum cholesterol, recipient age

64 or changes from baseline in HbA(1c), fasting serum glucose, bodyweight, and HbA(1c) targets of less t

65 of insects such as Drosophila also regulate serum glucose, but it remains unclear whether insulin is

66 is, fibrosis and inflammation while reducing serum glucose, cholesterol and triglyceride levels and l

67 Mean serum glucose, cholesterol, and triglyceride levels were

68 p diabesity, with no improvements in fasting serum glucose, cholesterol, weight, body composition, or

69 t interaction of the observed relations with serum glucose concentration (P < 0.05).

70 If validated prospectively, serum glucose concentration alone might be an indicator

71 A high-serum glucose concentration alters intraglomerular hemod

72 Diabetic rats had a mean serum glucose concentration of 490 mg/dl and consumed eq

73 lished vs. newly diagnosed disease), initial serum glucose concentration, and initial venous pH.

74 ; they also had significantly higher fasting serum glucose concentration, higher levels of markers of

75 he increase in activity was in proportion to serum glucose concentration.

76 hat may, in part, explain the observed lower serum glucose concentration.

77 H-linked substrates and these rats had lower serum glucose concentration.

78 ke (quartile 4) was associated with improved serum glucose concentrations (-3.39 and -2.72 mg/dL for

79 lding capacity, is still capable of reducing serum glucose concentrations and increasing glucose tole

80 High serum glucose concentrations are known to induce the pol

81 Serum glucose concentrations correlate directly with the

82 We find that serum glucose concentrations correlate with monocyte num

83 up given 600 mg of troglitazone, and fasting serum glucose concentrations decreased by 35 and 49 mg p

84 The median peak serum glucose concentrations for these two groups were 3

85 retion resulted in a transient correction of serum glucose concentrations in a mouse model of hypergl

86 ificantly impaired GTT and remarkably higher serum glucose concentrations in the fed state were obser

87 7.9% (2.3); 51% of patients had preoperative serum glucose concentrations more than 150 mg/dL; and 72

88 ically, animals exhibited randomly increased serum glucose concentrations not associated with impaire

89 st 24 hours after surgery was poor, and mean serum glucose concentrations of 150 mg/dL and higher dur

90 e associated with mean 24 hour postoperative serum glucose concentrations of 150 to 250 mg/dL (incide

91 dministered with Zot was sufficient to lower serum glucose concentrations to levels comparable to tho

92 the composite end points, the median initial serum glucose concentrations were 188 (interquartile ran

93 years and after six years by measurement of serum glucose concentrations while the subjects were fas

94 We compared the initial and peak serum glucose concentrations with hemodynamic variables

95 or insulin resistance and found it improved serum glucose concentrations, even without improving ins

96 nsulin application resulted in a decrease in serum glucose concomitant with an increase in serum porc

97 nicians to know when managing intraoperative serum glucose control.

98 Support Services hemoglobin A1c (HbA(c)) and serum glucose data.

99 In vitro ischemia (oxygen/serum/glucose deprivation) led to a progressive accumula

100 se-3 were processed to their active forms in serum-/glucose-deprived myocytes.

101 ts (55.4 +/- 15.3 years; 65.7% women) with a serum glucose determination on the day of surgery, posto

102 Graft rejection was determined by daily serum glucose determinations, and, at selected time poin

103 Correction for serum glucose did not significantly improve the accuracy

104 Low serum glucose, downregulation of glucose transporter-1 a

105 e killed on postburn days 1, 2, 5, and 7 and serum glucose, electrolytes, acute phase reactant protei

106 ight be associated with hepatic dysfunction, serum glucose elevation, inflammation and even severe ne

107 TRE improves glucose tolerance and decreases serum glucose excursions.

108 Sur2(-/-) animals had lower fasting and fed serum glucose, exhibited improved glucose tolerance duri

109 Fasting serum glucose fell from 198 mg/dL preoperatively to 94 m

110 ociation of post-cessation change in fasting serum glucose (FSG) with risk of fatty liver remains unc

111 of biopsy in 102 patients was normalized by serum glucose ([Glc]) to a standard of 100 mg/dL.

112 age, body mass index (BMI), blood pressure, serum glucose, glycosylated hemoglobin (HbA1c), blood ur

113 ratio TG/HDL-C, or impaired fasting glucose (serum glucose >/=110 mg/dL) to traditional risk factors

114 Hence, poor glycemic control (A1C >/=8% or serum glucose >/=200 mg/dL) appears to be associated wit

115 in day 11 embryos of severely diabetic rats (serum glucose >20 mmol/l).

116 Incident T2D was defined as fasting serum glucose >=126 mg/dL, HbA1C >=6.5%, or use of medic

117 (BP) 130 or diastolic BP 85 mmHg], elevated serum glucose (>100 mg/dL), and abdominal adiposity (wai

118 , and glucose control (diabetes medications, serum glucose, HbA(c), mean serum glucose within 24 hour

119 factors such as diabetes medication history, serum glucose, HbA1c, renal function, BMI, and blood pre

120 Fasting serum glucose, IAPP, and CA 19-9 were measured in 130 su

121 ma (PPARgamma) agonists developed to control serum glucose in patients with diabetes.

122 st of the insulin system, ensures sufficient serum glucose in times of fasting.

123 ouse model that correlated with reduction in serum glucose in tumor-bearing mice.

124 tic and hyperleptinemic as indicated by high serum glucose, insulin and leptin levels.

125 Let-7 levels strongly correlated with serum glucose, insulin and NEFA, and in vitro treatment

126 or (TFPI) antigen, and thrombin markers; and serum glucose, insulin, and electrolytes.

127 Fasting serum glucose, insulin, and hemoglobin A1C (HgbA1C) were

128 s study examined the relationship of fasting serum glucose, insulin, C-peptide, glycosylated hemoglob

129 piratory quotient (RQ), temperature, fasting serum glucose, insulin, free fatty acids, and ghrelin we

130 Serum glucose, insulin, IL-6, resistin, and OVA-specific

131 oys with subsequent repeated measurements of serum glucose, insulin, lipids, leptin, and calculated h

132 3(-/-) mice did not detect any alteration in serum glucose, insulin, or lipid levels; glucose or insu

133 After 30 d, serum glucose, insulin, triacylglycerol, total, LDL-chol

134 incorporating insulin secretion for a given serum glucose into the assessment of beta-cell function.

135 sion analysis, after controlling for gender, serum glucose, intraocular pressure, anterior chamber de

136 >5.9 or insulin use), and diabetes (fasting serum glucose level >=126 mg/dL [to convert to mmol/L, m

137 value (SUV), with and without correction for serum glucose level (SUV(gluc)); and to evaluate the use

138 Patients were stratified by serum glucose level on day 1 to 7 (low, 0-150 mg/dL; med

139 clusions, increased BP status or the fasting serum glucose level status were associated with cancer r

140 The group's mean serum glucose level was 6.0 mmol/L at the first visit an

141 p between average SUV or peak SUV and age or serum glucose level was observed.

142 score, systolic blood pressure reading, and serum glucose level was the best triage model for decisi

143 bles (eg, age, sex, baseline weight, fasting serum glucose level), diet variables (eg, carbohydrate c

144 iatrogenic hypoglycemia, particularly at low serum glucose levels (<3 mM).

145 GIK patients had lower serum glucose levels (138+/-4 versus 260+/-6 mg/dL; P<0.

146 adjuvant gemcitabine (n = 107) with elevated serum glucose levels (HgbA1C > 6.5%) exhibited improved

147 t and F2r, whose interaction associates with serum glucose levels across generations in high-fat-fed

148 Elevated serum glucose levels also correlated with the severity o

149 e, higher baseline body mass indexes, higher serum glucose levels and albuminuria, similar baseline s

150 sgene in wild-type mice resulted in elevated serum glucose levels and decreased ketone levels.

151 Activation of CAR significantly reduces serum glucose levels and improves glucose tolerance and

152 l TG mice displayed significant reduction in serum glucose levels and in hepatocyte glycogen storage

153 TNF-alpha administered to mice decreased serum glucose levels and increased muscle F2,6BP levels;

154 pathy in the absence of long-term effects if serum glucose levels are well monitored and controlled p

155 agic pancreatitis, all recipients maintained serum glucose levels at less than 130 mg/dL without insu

156 Maintaining serum glucose levels between 120 and 180 mg/dL with cont

157 Metformin lowers serum glucose levels by activating 5'-AMP-activated kina

158 Diabetes was confirmed by serum glucose levels exceeding 16 mmol/l during the expe

159 s (RR, 1.8 [CI, 1.1 to 3.0]) or preoperative serum glucose levels exceeding 16.6 mmol/L (RR, 3.7 [CI,

160 emonstrate in vivo by its ability to depress serum glucose levels in a dose-dependent manner.

161 (mean difference, 36; 95% CI, 25 to 47); and serum glucose levels of 95 mg per deciliter and 96 mg pe

162 injury was suggested by the observation that serum glucose levels were correlated with tubulointersti

163 Serum glucose levels were decreased in fasted mice and L

164 BLI signals and serum glucose levels were measured daily after transplan

165 Null animals had lower fasting serum glucose levels when compared with wild type contro

166 , systolic and diastolic blood pressure, and serum glucose levels with a requisite increase in the nu

167 oss of white blood cells and fluctuations of serum glucose levels, or patient preference.

168 in, resulting in stunted growth and elevated serum glucose levels, respectively.

169 ly with lowered insulin secretion, increases serum glucose levels, which stimulates de novo lipogenes

170 of the protein with respect to reduction of serum glucose levels.

171 hmias, daily step counts, sleep minutes, and serum glucose levels.

172 in obese (ob/ob) mice significantly lowered serum glucose levels.

173 nM); PTH(1-34) did not significantly change serum glucose, lipids, body weight, or fat mass.

174 Serum glucose, lipids, insulin, leptin, estradiol, and p

175 otential for use as dietary ingredients with serum glucose lowering activity in humans.

176 ressure <140/90 mm Hg, and untreated fasting serum glucose <100 mg/dL.

177 to 200 mg/dL) with GIK or standard therapy (serum glucose <250 mg/dL) using intermittent subcutaneou

178 e ingestion resulted in lower peak levels of serum glucose (mean difference, 41.0 mg/dL [95% CI, 27.7

179 A commercial laboratory measured serum glucose (non-fasting), albumin, cholesterol, high-

180 macrophage activation at baseline and after serum glucose normalization in obese type 2 diabetes (OT

181 te of <20 mmol/L (OR, 2.9; 95% CI, 1.6-5.6), serum glucose of >180 mg/dL (OR, 2.8; 95% CI, 1.6-4.8),

182 2 diabetes mellitus was identified based on serum glucose or HbA1c levels, the use of diabetes medic

183 not found between ICAM-1 and fasting or 2-h serum glucose or systolic or diastolic blood pressure.

184 d mortality predictability of A1C and random serum glucose over time in a contemporary cohort of 54,7

185 otein (HDL) cholesterol (<0.0001), decreased serum glucose (P < 0.001), increased calorie intake (P <

186 surface adipocyte areas (P < 0.0001), lower serum glucose (P = 0.04), lower serum insulin (P = 0.03)

187 on Comorbidity Index (r = 0.232, p < 0.001), serum glucose (r = 0.172, p < 0.001), BMI (r = 0.133, p

188 es that the use of hypothermia preserves CSF/serum glucose ratio, decreases CSF protein and nitric ox

189 nimum temperature and pH, and higher maximum serum glucose recorded.

190 en phosphorylase (Pygl) phosphorylation, and serum glucose, relative to WT.

191 enge attenuated the rise in the postprandial serum glucose response (P < 0.0001) and resulted in lowe

192 The strength of the serum glucose results after controlling for BMI suggests

193 ophils to lymphocytes ratio, platelet count, serum glucose, serum cholesterol, red blood cells were a

194 diabetes, as there were no abnormalities in serum glucose, serum insulin or the ability of insulin t

195 We included all fasting serum glucose tests taken between 2007-2014, of Clalit H

196 on class, ischemic etiology, statin use, and serum glucose, TFA levels were positively associated wit

197 impaired the ability of adiponectin to lower serum glucose, though other actions of the hormone were

198 Adiponectin lowers serum glucose through suppression of hepatic glucose pro

199 6 in Stockholm, Sweden, with measurements of serum glucose, total cholesterol, triglycerides, apolipo

200 2001, assessed body mass index, heart rate, serum glucose, triglycerides and high-density lipoprotei

201 The mean admission serum glucose value was 141 +/- 36 mg/dL (range, 64-418

202 ine levels can be used to estimate long-term serum glucose values and can be measured in frozen serum

203 lin doses were calculated based on predicted serum glucose values from corrected point-of-care glucom

204 Postoperative serum glucose values were available for 136 patients (79

205 Serum glucose values were elevated in the maternal sampl

206 Preoperative serum glucose values were similar between groups (309+/-

207 Serum glucose was also determined.

208 After 90 days, serum glucose was analyzed to document diabetes; alveola

209 Serum glucose was associated with hypertriglyceridemia w

210 The level of serum glucose was higher in methadone toxicity.

211 Serum glucose was measured at 6 hr after transplant and

212 Serum glucose was measured at each study visit in OPTIC

213 Phase 2 serum glucose was measured at weeks 1, 4, 15, and 21, wi

214 At the endpoint, the postprandial rise in serum glucose was reduced at 1 h by 1.3 mmol/l and at 2

215 roughout the study, the postprandial rise in serum glucose was significantly lower during insulin lis

216 Anthropometry and fasting serum glucose were measured, and lower-leg skeletal musc

217 Glycosylated hemoglobin, serum glucose while fasting, serum total cholesterol, hi

218 tes medications, serum glucose, HbA(c), mean serum glucose within 24 hours after surgery).